Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07219602 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | PHASE3 | RECRUITING | 300 | — | — | Dec 1, 2025 | Jun 1, 2028 | Mar 9, 2026 | - | — |
| NCT06305559 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | PHASE3 | RECRUITING | 300 | — | — | May 1, 2024 | Mar 1, 2027 | Jun 14, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily | DRUG | FDC |
| Obicetrapib 10 mg | DRUG | monotherapy |
| Placebo | OTHER | placebo on top of guideline-recommended lipid modifying therapy |